Moderate Dose of Tranexamic Acid and Complications after Valvular Heart SurgeryFunding None.
Background In valvular open-heart surgery, data regarding the effect of a moderate dose of tranexamic acid (TXA) on clinical outcomes are limited.
Methods Out of a cohort of 13,293 patients, we performed a propensity-score-matched analysis in 6,106 patients and assessed the risk of convulsive seizures (CS, primary endpoint), stroke, renal replacement therapy, and mortality (secondary endpoints). In the entire study cohort of 13,293 patients, we also assessed the multivariable-adjusted association of CS with postoperative outcomes.
Results The risk of CS was significantly higher in the TXA group (2.4%; n = 72) than in the non-TXA group (1.0%; n = 32), with a relative risk ratio (RR) of 2.28 (95% confidence interval [CI]: 1.50–3.47; p < 0.001). The risk of CS was also higher in patients receiving TXA doses ≥25 mg/kg body weight (3.7%; n = 40) than in patients receiving <25 mg/kg body weight (1.6%; n = 32; p < 0.001). Perioperative secondary clinical endpoints and 1-year mortality did not differ significantly between study groups (p-value > 0.05). Compared with non-CS patients (n = 13,000), patients with nonhemorrhagic, nonembolic CS (n = 253) revealed higher multivariable-adjusted in-hospital risks of stroke (RR: 3.82 [95% CI: 2.44–5.60; p < 0.001]) and mortality (RR: 2.07 [95% CI: 1.23–3.48; p = 0.006]), and a higher 1-year mortality risk (RR: 1.85 [95% CI: 1.42–2.41; p < 0.001]).
Conclusion A moderate TXA dose was associated with a significantly higher risk of seizure, but not with other clinical complications such as stroke, renal replacement therapy, and mortality. However, in the small group of patients experiencing a seizure, the risks of stroke and short- and mid-term mortality were substantially higher than in patients not experiencing a seizure, indicating that the use of a low-dose TXA protocol (<25 mg/kg body weight) should be considered.
Hulde, Nikolai; Zittermann, Armin; Deutsch, Marcus-Andre; von Dossow, Vera; Gummert, Jan; Koster, Andreas (2020), “Tranexamic acid and convulsive seizure,” Mendeley Data, V1, doi: 10.17632/4679m73bb3.1; http://dx.doi.org/10.17632/4679m73bb3.1.
Received: 12 October 2020
Accepted: 31 December 2020
04 March 2021 (online)
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Guo J, Gao X, Ma Y. et al. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. BMC Anesthesiol 2019; 19 (01) 129 DOI: 10.1186/s12871-019-0772-0.
- 2 Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol 2016; 79 (01) 18-26
- 3 Myles PS, Smith JA, Forbes A. et al; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376 (02) 136-148
- 4 Couture P, Lebon JS, Laliberté É. et al. Low-dose versus high-dose tranexamic acid reduces the risk of nonischemic seizures after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2017; 31 (05) 1611-1617
- 5 Sharma V, Katznelson R, Jerath A. et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia 2014; 69 (02) 124-130
- 6 Goldstone AB, Bronster DJ, Anyanwu AC. et al. Predictors and outcomes of seizures after cardiac surgery: a multivariable analysis of 2,578 patients. Ann Thorac Surg 2011; 91 (02) 514-518
- 7 Koster A, Börgermann J, Zittermann A, Lueth JU, Gillis-Januszewski T, Schirmer U. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. Br J Anaesth 2013; 110 (01) 34-40
- 8 Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17 (04) 343-346
- 9 Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis 2019; 30 (01) 1-10
- 10 Grassin-Delyle S, Tremey B, Abe E. et al. Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2013; 111 (06) 916-924
- 11 Hulde N, Zittermann A, Deutsch MA, von Dossow V, Gummert JF, Koster A. Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function. Interact Cardiovasc Thorac Surg 2020; 30 (04) 538-540
- 12 Ivascu NS, Gaudino M, Lau C. et al. Nonischemic postoperative seizure does not increase mortality after cardiac surgery. Ann Thorac Surg 2015; 100 (01) 101-106
- 13 Myles PS, Smith JA, Kasza J. et al; ATACAS investigators and the ANZCA Clinical Trials Network. Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. J Thorac Cardiovasc Surg 2019; 157 (02) 644-652.e9
- 14 Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42 (12) 1843-1850